Progress report on new antiepileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI)

Epilepsy Research

Volumn 51, Issue 1-2, 2002, Pages 31-71

  Bialer, M ^a   Johannessen, S I ^b   Kupferberg, H J ^c   Levy, R H ^d   Loiseau, P ^e   Perucca, E ^f  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b National Center for Epilepsy   (Norway)

^c Kupferberg Consultants   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e HÔPITAL PELLEGRIN   (France)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptic drugs; Clinical trials; Conference; Drug development; Epilepsy; Pharmacology

Indexed keywords

ANTICONVULSIVE AGENT; CARABERSAT; CARBAMAZEPINE; CONANTOKIN G; DEPAKOTE DR; DIGOXIN; DIZOCILPINE; ETIRACETAM; FOSPHENYTOIN SODIUM; GABAPENTIN; HARKOSERIDE; IFENPRODIL; LAMOTRIGINE; METFORMIN; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENYTOIN; PLACEBO; PREGABALIN; RETIGABINE; SAFINAMIDE; SPD 421; TALAMPANEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VALROCEMIDE; VIGABATRIN; WARFARIN; ZONISAMIDE;

AGITATION; AMNESIA; ARTICLE; ASTHENIA; ATAXIA; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECT; DRUG METABOLISM; EPILEPSY; EPILEPTOGENESIS; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IRRITABILITY; ITALY; NAUSEA; NERVOUSNESS; NEUROLOGY; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; QT INTERVAL; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; TERATOGENESIS; TREMOR; VERTIGO;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS; EPILEPSY; HUMANS; PROGRAM DEVELOPMENT; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036752811     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00106-7     Document Type: Article

References (136)

1. Anderson G.D., Gila B.E., Gillian F., Messenheimer J. Evaluation of lamotrigine pharmacokinetics during conversion to monotherapy: time course of deinduction from carbamazepine or phenytoin. Neurology. 56 (Suppl. 3):2001;A330-A331.
2. Angehagen M., Shank R., Hansson E., Ronnback L., Ben-Menachem E. Topiramate affects the ability of cAMP-activated protein kinase to phosphorylate glutamate receptors activated by kainate. Epilepsia. 42 (Suppl. 7):2001;10.
3. Annegers J.F., Coan S.P., Hauser W.A., Leestma J. Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. Epilepsia. 41:2000;549-553.
4. The Gabapentin Pediatric Study Group, Appleton R., Fichtner K., LaMoreaux L., Alexander J., Halsall G., Murray G., Garofalo E. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicenter, double-blind, placebo-controlled study. Epilepsia. 40:1999;1147-1154.
5. Appleton R.E., Peters A.C.B., Mumford J.P., Shaw D.E. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia. 40:1999;1627-1633.
6. Barcs G., Walker E.B., Elger C.E., et al. Oxcarbazepine: placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 42:2000;1597-1607.
7. Bazan N.G., Birkle D.L., Tang W., Reddy T.S. The accumulation of free arachidonic acid, diacylglycerols, prostaglandins, and lipoxygenase reaction products in the brain during experimental epilepsy. Adv. Neurol. 44:1986;879-902.
8. Belayev L., Alonso O.F., Liu Y., Chappell A.S., Zhao W., Ginsberg M.D., Busto R. Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats. J. Neurotrauma. 18:2001;1031-1038.
9. The European Levetiracetam Study Group, Ben-Menachem E., Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia. 41:2000;1276-1283.
10. Ben-Menachem E., Smith U., Hellstrom K., Stagge A. Predictors of weight loss in patients with epilepsy treated with topiramate. Epilepsia. 42 (Suppl. 7):2001;252.
11. Bergmann A., Bauer J., Stodieck S. Treatment of epilepsy with tiagabine as add-on antiepileptic drug in patients with refractory seizures: experiences in 574 patients. Epilepsia. 41 (Suppl. 6):2000;40.
12. Beydoun A., Sachdeo R.C., Rosenfeld W.E., et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology. 54:2000;2245-2251.
13. Beydoun A., Sachdeo R.C., Rosenfeld W.E., D'Souza J. Long-term safety and efficacy of oxcarbazepine in patienst with refractory partial epilepsy. Epilepsia. 42 (Suppl. 7)##:2001;176-177.
14. Beydoun A., Schmidt D., D-Souza J. Meta-analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. J. Pain. 3 (Suppl. 1):2002;38.
15. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E. Progress report on new antiepileptic drugs: a summary of the third eilat conference. Epilepsy Res. 25:1996;299-319.
16. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth eilat conference (EILAT IV). Epilepsy Res. 34:1999;1-41.
17. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth eilat conference (EILAT V). Epilepsy Res. 43:2001;11-58.
18. Bill P.A., Vigonius U., Pohlmann H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 27:1997;195-204.
19. Binks A.P., Paydarfar D., Schachter S.C., et al. High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects. Respir. Physiol. 127:2001;125-133.
20. Biton V., Mirza W., Montouris G., Vuong A., Hammer A.E., Barret P.S. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 56:2001;172-177.
21. Bleakman D., Ballyk B.A., Schoepp D.D., Palmer A.J., Bath C.P., Sharpe E.F., Woolley M.L., Bufton H.R., Kamboj R.K., Tarnawa I., Lodge D. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology. 35:1996;1689-1702.
22. Blotnik S., Bergman F., Bialer M. The disposition of valproyl glycinamide and valproyl glycine in rats. Pharm. Res. 14:1997;873-878.
23. Bowden C., Calabrese J., Akthar S., Olajossy M., Montgomery S., Montgomery P., Ascher J., Earl N. Lamotrigine demonstrates long term mood stabilization in manic patients. Bipolar Disord. 3 (S1):2001;27-28.
24. The 945-212 Study Group, Brodie M.J., Anhut H., Murray G., Maton S. Gabapentin versus lamotrigine monotherapy: a double-blind comparison. Epilepsia. 41 (Suppl. 6):2000;138-139.
25. Cantrell D., Cloyd J., Gates J., Kanner A., Kuznlecky R., Labiner D., Montouris G., Morris G., Naritoki D., Pellock J., Ramsay E., Vazquez, Wheless J. Rapid infusions of valproate sodium injection (Depacon®) are safe and well tolerated. Epilepsia. 41 (Suppl. 7):2000;253.
26. Carrazana E., Beydoun A., Kobetz S., Constantine S. An open-label, prospective trail of oxcarbazepine in the treatment of painful diabetic neuropathy. J. Pain. 3 (Suppl. 1):2002;28.
27. Christe W., Kramer G., Vigonius U., et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 26:1997;451-460.
28. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23:2001;1296-1310.
29. Collins S.D., Cavanaugh J., Elisseou M., Lamm J., Sommerville K.W. Depakote CR: biopharmaceutical and pharmacokinetic studies of a new formulation for once daily dosing. Neurology. 50 (Suppl. 4):1998;50.
30. Czuczwar S.J., Swiader M., Kuzniar H., Gasior M., Kleinrok Z. LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. Eur. J. Pharmacol. 359:1998;103-109.
31. Dam M., Ekberg R., Løyning Y., Waltimo O., Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 3:1989;70-76.
32. DeGiorgio C.M., Schachter S.C., Handforth A., et al. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia. 41:2000;1195-1200.
33. Demarest K., Conway B., Osborne M., Chen X. Topiramate improves glucose tolerance and may improve insulin sensitivity in animal models of type 2 diabetes mellitus. Diabetes. 50 (Suppl. 2):2001;A302.
34. Devinsky O., Leppik H., Willmore L.J., Pellock J.M., Dean C., Gates J., Ramsay R.E. Safety of intravenous valproate. Ann. Neurol. 38:1995;670-674.
35. Donevan S.D., McCabe R.T. Conantokin G is an NR2B selective competitive antagonist of NMDA receptors. Mol. Pharmacol. 58:2000;614-623.
36. Drake M.E., Kay A.M., Knapp M.S., Greathouse N.J. An open-label trial of tiagabine for migraine prophylaxis. Headache. 39:1999;352.
37. ® Delayed-Release (DR) formulation in healthy volunteers. Epilepsy Res., in press.
38. Edwards K.R., Sackellares J.C., Vuong A., Hammer A.E., Barrett P.S. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav. 2:2001;28-36.
39. Eisenberg E., Lurie Y., Braker C., Daoud D., Ishay A. Lamotrigine reduces painful diabetic neuropathy. Neurology. 57:2001;505-509.
40. Emrich H.M., Altmann H., Dose M., et al. Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacol. Biochem. Behav. 19:1983;369-372.
41. Fariello R.G., McArthur R.A., Bonsignori A., Cervini M.A., Maj R., Marrari P., Pevarello P., Wolf H.H., Woodhead J.W., White H.S., Varasi M., Salvati P., Post C. Preclinical evaluation of PNU i51774E as a novel anticonvulsant. J. Pharmacol. Exp. Ther. 285:1998;397-403.
42. Fariello R.G., Maj R., Marrari P., Salvati P. Acute behavioural and EEG effects of NW-1015 on electrically induced afterdischarge in conscious monkeys. Epilepsy Res. 39:2000;37-46.
43. Faught E., Ayala R., Monotouris G.G., Leppik I.E. Randomized controlled trial of zonisamide for the treatment vof refartory partial-onset seizures. Neurology. 57:2001;1774-1779.
44. Ferron G.M., Paul J., Fruncillo R., Richards L., Knebel N., Getsy J., Troy S. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J. Clin. Pharmacol. 42:2002;175-182.
45. Fischer J.H., Cwik M.J., Luer M.S., Sibley C.B., Deyo K.L. Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes. Ann. Pharmacother. 31:1997;553-559.
46. Frei M.G., Osorio I. Left vagus nerve stimulation with the neurocybernetic prosthesis has complex effects on heart rate and on its variability in humans. Epilepsia. 42:2001;1007-1016.
47. French J.A., Malicsi M.J.R., Kugler A.R., Knapp L.E., Bockbrader H.N., Garofalo E.A. Pregabalin adjunctive therapy in patients with partial seizures. Epilepsia. 40 (Suppl. 7):1999;106.
48. Freitag F.G., Diamond S., Diamond M.L., Urban G.J., Pepper B.J. An open use trial of tiagabine in migraine. Headache. Q11:2000;133-134.
49. Gidal B.E., Nanry K.P., Sheth R.D., Parnell J., Barrett P., Hutson P.R. Lamotrigine pharmacokinetics in the presence of low-dose valproic acid (VPA) and during conversion to monotherapy. Epilepsia. 42 (Suppl. 7):2001;89.
50. Glauser T.A., Nigro M., Sachdeo R.C., et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology. 54:2000;2237-2244.
51. Glauser T.A., Nigro M., Sachdeo R.C., Beydoun A., D'Souza J. Long-term efficacy and safety of adjunctive-oxcarbazepine therapy in children with partial onset seizures. Epilepsia. 42 (Suppl. 7):2001;54.
52. Guberman A., Neto W., Gassman-Mayer C. Efficacy of 200 mg/day topiramate in treatment-resistant partial seizures when added to an enzyme-inducing antiepileptic drug. Epilepsia. 42 (Suppl. 7):2001;179.
53. Guerreiro M.M., Vigonius U., Pohlmann H., et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 27:1997;205-213.
54. Hadad S., Bialer M. Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. Pharm. Res. 12:1995;1160-1163.
55. Harding G.F., Spencer E.L., Wild J.M., Conway M., Bohn R.L. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children. Neurology. 58:2002;1261-1265.
56. Harding G.F., Wild J.M., Robertson K.A., Rietbrock S., Martinez C. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology. 55:2000;347-352.
57. Hempel R., Schupke H., McNeilly P.J., Heinecke K., Kronbach C., Grunwald C., Zimmermann G., Griesinger C., Engel J., Kronbach T. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab. Dispos. 27:1999;613-622.
58. 3]-SB-204269, a radiolabelled form of the new anticonvulsant SB-204269, to a novel binding site in rat brain membrane. Br. J. Clin. Pharmacol. 121:1997;1687-1691.
59. Hermann R., Ferron G.M., Knebel N., Paul J., Richards L.S., Ruus P. Effects of age and gender on the pharmacokinetics of retigabine. Epilepsia. 41 (Suppl. 7):2000;115.
60. Herreroa, A.I., Solisa, J.M., Del Olmoa, N., Gonzalez-Escaladab, J.R., 2002. New actions of the anticonvulsant topiramate. Neuropharmacology (in press).
61. Hiller A., Nguyen N., Strassburg C.P., Li Q., Jainta H., Pechstein B., Ruus P., Engel J., Tukey R.H., Kronbach T. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab. Dispos. 27:1999;605-612.
62. Hirsch E., De Saint-Martin A., Marescaux C. Benign neonatal familial convultions: a model of idiopathic epilepsy. Rev. Neurol. 155:1999;463-467.
63. Horváth K. Highlights of CNS research at IDR: 2,3-benzodiazepines. Pharmazie. 56 (Suppl. 1):2001;S56-S61.
64. Isoherranen N., White H.S., Finnell R.H., Woodhead J.H., Bennett G.D., Bialer M. Anticonvulsant activity and teratogenicity of valrocemide (TV1901). Epilepsia. 42 (Suppl. 7):2001;212.
65. Isoherranen N., Woodhead J.H., White H.S., Bialer M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia. 42:2001;831-836.
66. Kalviainen R., Nousianen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs. 15:2001;217-230.
67. Kälviäinen R., Hache J.-C., Renault-Djouadi J. A study of visual fields in patients receiving tiagabine as monotherapy versus carbamazepine or lamotrigine monotherapy. Epilepsia. 42 (Suppl. 7):2001;256.
68. Kanard, R., et al., 2000. Treatment of painful sensory neuropathy with tiagabine hydrochloride. Poster presented at International Symposium on the Autonomic Nervous System, Rio Grande, Puerto Rico, October 27-29.
69. Kanba S., Yagi G., Kamijima K., Suzuki T., Tajima O., Otaki J., Arata E., Koshikawa H., Nibuya M., Kinoshita N. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog. Neuropsychopharmacol. Biol. Psychiatry. 18:1994;707-715.
70. Kirby, L.C., et al., 1999. Tiagabine (Gabitril) in the management of painful diabetic polyneuropathy. Poster presented at American Pain Society; Fort Lauderdale, FL, October 21-22.
71. Knapp L.E., Kugler A.R., Eldon M.A. Fosphenytoin: pharmacokinetics and administration. Emerg. Med. 28 (Suppl. 4):1996;9-16.
72. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54:2000;1589-1595.
73. Koo B.K., Ham S.D., Canady A., Sood S. EEG changes with vagus nerve stimulation and clinical application of these changes to determine optimum stimulation parameters. Epilepsia. 41 (Suppl. 7):2000;226.
74. Krämer G., Edrich P. Levetiracetam in elderly patients with epilepsy. Epilepsia. 42 (Suppl. 7):2001;142.
75. Krakow K., Walker M., Otoul C., Sander J.W.A.S. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 56:2001;1772-1774.
76. Lee W.T., Shen Y.Z., Chang C. Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitroproionic acid: evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy. Neuroscience. 95:2000;89-95.
77. Lees G.J. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs. 59:2000;33-78.
78. Leiderman D.B. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials. Epilepsia. 35:1994;74-76.
79. Leppik I.E., French J.A., Ferrendelli J.A., Katos M.G., Morrell M.J. An early view of results from the K.E.E.P.E.R. trial: a phase iv community-based clinical trial investigating levetiracetam as add-on therapy in partial-onset seizures. Epilepsia. 42 (Suppl. 7):2001;154.
80. Loscher W., Honack D. Anticonvulsant and antiepileptogenic effect of L-deprenyl (selegiline) in the kindling model of epilepsy. J. Pharmacol. Exp. Ther. 274:1995;307-314.
81. Mandelbaum D.E., Kugler S.L., Wenger E.C., Wollack J.B., Venkat A. Clinical experience with levetiracetam and zonisamide in children with uncontrolled epilepsy. Epilepsia. 42 (Suppl. 7):2001;182.
82. Magnus L. Non-epileptic uses of gabapentin. Epilepsia. 40 (Suppl. 6):1999;S66-72.
83. Matagne A.C., Baltes E., Coupez R., Patsalos P.N., Kiltgaard H.V. Levetiracetam enhances markedly the seizure suppression of other antiepileptic drugs in audiogenic susceptible mice. Epilepsia. 42 (Suppl. 7):2001;82.
84. Mateo C.I., Fix A.F., Jacobson M.P., French J.A. Clinical experience with levetiracetam: reported adverse events. Epilepsia. 42 (Suppl. 7):2001;257-258. (abstract).
85. Mathias S., Wetter T.C., Steiger A., Lancel M. The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol. Aging. 22:2001;247-253.
86. McCumber D., Chen K.S., Meyer K.B., Yaksh T.L. A study of zonisamide (Zonegran®) in the formalin model of nociception. J. Pain. 3 (Suppl. 1):2002;29.
87. McJilton J., DeToledo J., DeCerce J., et al. Cotherapy of lamotrigine/zonisamide results in significant elevation of zonisamide levels. Epilepsia. 37 (Suppl. 5):1996;173. (abstract).
88. McLean M.J., Schmutz M., Wamil A.W., et al. Oxcarbazepine: mechanisms of action. Epilepsia. 35 (Suppl. 3):1994;S5-S9.
89. Murata, M., Horiuchi, E., Kanazawa, I., 2001. Mechanism of action of zonisamide against Parkinson's disease. Presented at 42nd Annual Conference of the Japan Neurology Association, Tokyo, Japan, May 11-13, 2001.
90. Murata M., Horiuchi E., Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci. Res. 41:2001b;397-399.
91. Meador K.J., Loring D.W., Ray P.G., Murro A.M., King D.W., Perrine K.R., Vazquez B.R., Kiolbasa T. Differential cognitive and behavorial effects of carbmazepine and lamotrigine. Neurology. 56:2001;1177-1182.
92. Meador K.J., Hulihan J., Kamin M., Karim R. Topiramate and valproate added to carbamazepine: effect on objective measures of cognitive function in adults with epilepsy. Epilepsia. 42 (Suppl. 7):2001;251-252.
93. Morrell M.J., Isojarvi J.I.T., Gomez G.M.A., O'Neill F., Risner M. Cross-sectional study comparing weight gain and androgen levels in women with epilepsy taking lamotrigine compared to valproate monotherapy. Neurology. 56 (Suppl. 3):2001;A234.
94. Nousiainen I., Mäntyjärvi M., Kälviäinen R. Visual function in patients treated with the GABAergic anticonvulsant drug tiagabine. Clin. Drug Invest. 20:2000;393-400.
95. Nousianen I., Maniyarvi M., Kalviainen R. No reversion in vigabatrin-associatred visual field-defects. Neurology. 57:2001;1916-1917.
96. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther. 85:2000;77-85.
97. Paul S.R., Krauss G.L., Miller N.R., Medura M.T., Miller T.A., Johnson M.A. Visual field function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. Epilepsia. 42:2001;525-530.
98. Pevarello P., Bonsignori A., Dostert P., Heidemperger F., Pinciroli V., Colombo M., McArthur R.A., Salvati P., Post C., Fariello R.G., Varasi M. Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl)amino]alkanamide derivatives. J. Med. Chem. 41:1998;579-590.
99. Poolos N.P., Johnston D. Lamotrigine decreases the excitability of dendrites in hippocampal pyramidal neurons by increasing activation of Ih. Epilepsia. 42 (Suppl. 7):2001;82-83.
100. Privitera M.D., Brodie M.J., Neto W., Wang S. Topiramate vs. investigator choice of carbamazepine or valproate as monotherapy in newly diagnosed epilepsy. Epilepsia. 41 (Suppl. 7):2001;93.
101. Roepstorff A., Lambert J.D.C. Comparison of the effect GABA uptake inhibitor blockers, tiagabine and nipecotic acid, on inhibitory synaptic efficacy in hippocampal CA1 neurones. Neurosci. Lett. 146:1992;131-134.
102. Ramsay R.E., Kugler A.R., Anhut H., Smith T.M., Robbins J.L., Knapp L.E., Garofalo E.A. Pregabalin adjunctive therapy in patients with partial seizures. Epilepsia. 42 (Suppl. 7):2001;211.
103. Richard D., Ferland J., Lalonde J., Samson P., Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition. 16:2000;961-966.
104. Ring H.A., White S., Costa D.C., et al. A SPECT study of the effect of vagal nerve stimulation on thalamic activity in patients with epilepsy. Seizure. 9:2000;380-384.
105. Robbins J.L., Kugler A.R., Anhut H., Smith T.M., Garofalo E.A. Pregabalin shows anticonvulsant activity onset by second day. Epilepsia. 42 (Suppl. 7):2001;211.
106. Rostock A., Tober C., Rundfeldt C., Bartsch R., Engel J., Polymeropoulos E.E., Kutscher B., Loscher W., Honack D., White H.S., Wolf H.H. D-23129: a new anticonvulsant with a braod spectrum activity in animal models of epileptic seizures. Epilepsy Res. 23:1996;211-223.
107. Rundfeldt C., Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci. Lett. 281:2000;73-76.
108. Rush A.J., George M.S., Sackeim H.A., et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol. Psychiatry. 47:2000;276-286.
109. Sachdeo R., Edwards K., Hasegawa H., et al. Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent-onset partial epilepsy. Neurology. 52 (Suppl. 2):1999;A391. (abstract).
110. Sachdeo R., Beydoun A., Schachter S.C., et al. Oxcarbazepine (trileptal) as monotherapy in patients with partial seizures. Neurology. 57:2001;864-871.
111. Sachdeo R., Wasserstein A., Mesenbrink P., D'Souza J. Effects of oxcarbazepine on sodium concentrations and water handling. Ann. Neurol. 51:2002;613-620.
112. Salvati P., Maj R., Caccia C., Cervini M.A., Fornaretto M.G., Lamberti E., Pevarello P., Skeen G.A., White H.S., Wolf H.H., Faravelli L., Mazzanti M., Mancinelli E., Varasi M., Fariello R.G. Biochemical and electrophysiological studies on the mechanisms of action of PNU 151774E, a novel antiepileptic compound. J. Pharmacol. Exp. Ther. 288:1999;1151-1159.
113. Schachter S.C., Vazquez B., Fisher R.S., et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 52:1999;732-737.
114. Schmidt D., Jacob R., Loiseau P., Deisenhammer E., Klinger D., Despand A., Egli M., Bauer G., Stenzel E., Blankenhorn V. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 15:1993;67-73.
115. Shapiro D.Y., Nordli D., Glauser T.A., Knapp L.E., Greiner M., Purcell T., Brigell M., Fichtner K., Kugler A.R., Malicsi M., Smith T.M., Garofalo E. Gabapentin add-on therapy for refractory partial seizures in children 1-36 months of age: efficacy in a novel, short-term, placebo-controlled trial. Epilepsia. 41 (Suppl. 7):2000;106.
116. Shellenberger, K., Shah, J., Dunkley, D., Floren, L., 2001. Multiple-dose pharmacokinetics of antiepilepsy drugs in the presence of zonisamide. Presented at Zonegran Scientific Exhibit at the American Epilepsy Society Annual Meeting, Philadelphia, PA, December 4, 2002.
117. Sills G.J., Butler E., Thompson G.G., Brodie M. Vigabatrin and tiagabine are pharmacologically different drugs. A preclinical study. Seizure. 8:1999;404-411.
118. Sills G.J., Patsalos P.N., Butler E., Forrest G., Ratnaraj N., Brodie M. Visual field constriction: Accumulation of vigabatrin but not tiagabine in the retina. Neurolgy. 57:2001;196-200.
119. A receptors expressed in Xenopus oocytes. Epilepsia. 42 (Suppl. 7):2001;14.
120. Smith T., Groom A., Zhu B., Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6:2000;62-66.
121. Spiegelstein O., Yagen B., Bialer M. Structure-pharmacokinetic-pharmacodynamic relationships of the new antiepileptic drug valproyl glycinamide. Epilepsia. 40:1999;545-552.
122. Stefani A., Pisani A., De Murtas M., et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia. 36:1995;997-1002.
123. The Epilepsy Observational Investigation Group of Spain, Salas-Puig J., Arroyo S. Tiagabine adjunctive therapy: an observational study. Epilepsia (Florence). 41:2000;40.
124. The European Levetiracetam Study Group, Shorvon S.D., Lowenthal A., Janz D., Bielen E., Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia. 41:2000;1179-1186.
125. The International Gabapentin Monotherapy Study Group 945-77, Chadwick D.W., Anhut H., Greiner M.J., Alexander J., Murray G.H., Garofalo E.A., Pierce M.W. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology. 51:1998;1282-1288.
126. The Study Group, Czapinski P., Jedrzejczak J., Kozik A., Wendorff J., Sobaniec W., Grygolec P. Open multicentre study of tiagabine as add on treatment in patients with partial seizures. Epilepsia. 41 (Suppl. 6):2000;40.
127. The United States Levetiracetam Study Group, Cereghino J.J., Biton V., Abou-Khali B., Dreifuss F., Gauer L.J., Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 55:2000;236-242.
128. Thibault, M., Blume, W., St. Hilaire, J., Zakhari, R., Sommerville, K.W., 2001. Extended-release vs. enteric-coated formulations of divalproex sodium: Results of a randomized, crossover study of epileptic patients with primary generalized seizures. Focus on Epilepsy, Quebec, July.
129. Tober C., Rostock A., Rundfeldt C., Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol. 303:1996;163-169.
130. Tomlinson, D.R., Malcangio, M., Patel, J., Meyer, K.B., Chen, S., 2000. Effects of zonisamide on mechanically-induced nociception in rates with streptozotocin-diabetes. In: Worldwide Pain Conference Proceedings, Program and Abstracts of the Worldwide Pain Conference, July 15-21, 2000, San Francisco, CA, p. 160.
131. Upton N., Blackburn T.P., Campbell C.A., Cooper D., Evans M.L., Herdon H.J., King P.D., Ray A.M., Stean T.O., Chan W.N., Evans J.M., Thompson M. Profile of SB-204269, mechanistically novel anticonvulsant drug, in rat nmodels of focal and generalized epilepsy seizures. Br. J. Clin. Pharmacol. 121:1997;1679-1686.
132. Vestergaard K., Andersen G., Gottrup H., Kristensen B.T., Jensen T.S. Lamotrigine for central poststroke pain. Neurology. 56:2001;184-190.
133. Wild J.M., Martinez C., Reinshagen G., Harding G.F. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia. 40:1999;1784-1794.
134. Williams, L., Carothers, L., Schweitzer, S., Ashbrenner, E., Dutta, S., Sommerville, K.W., 2001. Bioavailability of valproate from divalproex sodium extended-release relative to divalproex sodium delayed-release under different non-fasting regimens. American Epilepsy Society, Industry Sponsored Symposium, December 2001.
135. Wilson E.A., Sills G.J., Forrest G., Brodie M.J. High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. Epilepsy Res. 29:1998;161-166.
136. Zagon A., Kemeny A.A. Slow hyperpolarization in cortical neurons: a possible mechanism behind vagus nerve simulation therapy for refractory epilepsy? Epilepsia. 41:2000;1382-1389.